Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for grant applications to generate and conduct preliminary tests of targeted smoking cessation treatments for individuals with schizophrenia. Smokers with schizophrenia who have co-occurring alcohol and/or substance abuse disorders are also a population of interest.

This FOA encourages Phased Innovation (R21/R33) applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of nicotine addiction in individuals with schizophrenia, and clear hypotheses about how an intervention directed at changing the target can lead to clinical benefits.

Studies of novel interventions include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches and targets thereof. This FOA provides support for up to two years (R21 phase) for protocol development and target identification and engagement studies, followed by up to 3 years of support (R33 phase) for exploratory/pilot studies to further evaluate target engagement and its prospective association with clinical benefits, and to evaluate the feasibility of conducting a larger trial.

Companion FOA: PAR-14-231, R33 Exploratory/Developmental Grants Phase II

Deadlines:

  • Letter of Intent Due Date(s): 30 days before the application due date
  • Application Due Date(s): August 15, 2014, December16, 2014, April 15, 2015, August 17, 2015, December 15, 2015, April 15, 2016, August 16, 2016, December 15, 2016, April 17, 2017, by 5:00 PM local time of applicant organization.
  • AIDS Application Due Date(s): August 15, 2014, December16, 2014, April 15, 2015, August 17, 2015, December 15, 2015, April 15, 2016, August 16, 2016, December 15, 2016, April 17, 2017, by 5:00 PM local time of applicant organization.

PAR-14-230 Expiration Date April 18, 2017

Agency Website

Amount

$450,000

Amount Description

The R21 phase may not exceed two years or $275,000 in direct costs, with no more than $150,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed three years or $450,000 in direct costs, with no more than $225,000 in direct costs in any single year of the R33 phase. Application budgets need to reflect the actual needs of the proposed project.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science

External Deadline

April 17, 2017